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Original Article
Purpose: Cardiovascular effects of hypothyroidism are well known. Osteopontin (OPN) is a new inflammatory marker which was first isolated 
from the bone. Flow-mediated dilatation (FMD), a noninvasive technique to measure this endothelium-dependent function, has been used in 
several clinical studies to show cardiovascular risks. The aim of our study was to assess FMD value in hypothyroidism patients and to investigate 
whether plasma OPN level is a parameter which can predict cardiovascular risks in this group of patients. 
Material and Method: This study included 39 patients who had high levels of thyroid-stimulating hormone (TSH) and 11 healthy euthyroid 
controls. Plasma TSH, free thyroxine, fibrinogen, high-sensitive C-reactive protein (hsCRP), fasting plasma glucose, total cholesterol (T-chol), low 
density lipoprotein (LDL), triglyceride and OPN levels were measured at the time hypothyroidism was first detected and after euthyroid state was 
achieved with levothyroxine treatment. In parallel with these assessments, brachial FMD measurements were also performed. 
Results: In hypothyroid patients cardiovascular risk factors such as T-chol, LDL and triglyceride levels were higher than in control group but 
fibrinogen and hsCRP levels were not different between the groups. OPN levels were similar in patient and control groups, but basal FMD levels 
were lower in patients with hypothyroidism. After euthyroidism was achieved, OPN levels significantly decreased and FMD levels significantly 
increased, but a correlation was not detected between these two parameters. 
Discussion: Our study did not show a significant correlation between OPN and cardiovascular risk parameters. Further studies are needed to 
use OPN as a cardiovascular risk marker in hypothyroid patients. 
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Amaç: Hipotiroidinin kardiyovasküler etkileri iyi bilinmektedir. Osteopontin (OPN), ilk olarak kemikten izole edilmiş olan yeni bir enflamatuvar 
belirteçtir. Akım aracılı dilatasyon (AAD), çeşitli klinik çalışmalarda kardiyovasküler riski göstermek için kullanılan invaziv olmayan bir tekniktir. 
Çalışmamızın amacı, hipotiroidi hastalarında AAD’yi değerlendirmek ve bu grup hastalarda kardiyovasküler riski değerlendirmekte plazma OPN 
düzeyinin bir parametre olarak kullanılıp kullanılmayacağını değerlendirmektir.
Gereç ve Yöntem: Bu çalışma, tiroid uyarıcı hormon (TSH) düzeyi yüksek 39 hasta ve 11 sağlıklı kontrol içermekteydi. Hipotiroidi ilk tespit edildiğinde 
ve levotiroksin tedavisi ile ötiroidi sağlandıktan sonra, plazma TSH, serbest tiroksin, fibrinojen, yüksek duyarlı C-reaktif protein (hsCRP), açlık 
plazma glukozu, total kolesterol, düşük yoğunluklu lipoprotein (LDL) kolesterol, trigliserid ve OPN düzeyleri ölçüldü. Bu değerlendirmelere ek 
olarak brakial arterden AAD ölçümü yapıldı.
Bulgular: Hipotiroidi hastalarında total kolesterol, LDL kolesterol ve trigliserid gibi kardiyovasküler risk faktörleri kontrol grubundan daha yüksekti, 
ancak fibrinojen ve hsCRP düzeyleri gruplar arasında farklı değildi. OPN düzeyi, hasta ve kontrol grubunda benzerdi fakat, bazal AAD düzeyi 
hipotiroidi olan hastalarda daha düşüktü. Ötiroidi sağlandıktan sonra, OPN düzeyleri anlamlı derecede azaldı ve AAD düzeyleri anlamlı derecede 
arttı fakat bu iki parametre arasında korelasyon saptanamadı.
Tartışma: Çalışmamız OPN ve kardiyovasküler risk parametreleri arasında anlamlı bir korelasyon olduğunu gösterememiştir. Hipotiroidi 
hastalarında bir kardiyovasküler risk belirteci olarak OPN kullanımı için ilave çalışmalar gereklidir.
Anahtar kelimeler: Hipotiroidi, osteopontin, akım aracılı dilatasyon, ateroskleroz
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Introduction
Hypothyroidism is a prevalent hormonal disorder characterized by 
decreased thyroid hormone. It may develop due to dysfunctions 
in the thyroid (primary) or pituitary gland (secondary). Primary 
hypothyroidism is responsible from approximately 99% of all 
cases (1). In regions where iodine amount is sufficient, the most 
common cause of hypothyroidism is Hashimoto’s thyroiditis. The 
incidence of hypothyroidism is between 0.5% and 1.9% in women 
and <1% in men and subclinic hypothyroidism is 3-13.6% in 
women and 0.7-5.7% in men (2). 
Hypothyroidism is known to be an important risk factor for 
cardiovascular diseases. High blood pressure, high levels of 
low density lipoprotein (LDL), high-sensitive C-reactive protein 
(hsCRP), homocystein, plasminogen activator inhibitor-1 (PAI-1) 
and D-dimer levels in circulation, and endothelial dysfunction are 
commonly associated with atherogenic risk factors. However, 
there is not a marker unique to hypothyroidism which can directly 
show increased cardiovascular risks in hypothyroidism patients 
(3,4,5,6,7). 
Osteopontin (OPN), which is associated with immune system, 
inflammation and several malignancies, is a new inflammatory 
marker isolated from bone. Other than osteoblasts and 
osteoclasts, it is also synthesized in and released from 
macrophages, T cells, hematopoietic cells, vessel smooth muscle 
cells, fibroblasts, and myocardial cells. OPN has roles mainly in 
cellular immunity, cellular migration and infiltration, tissue repair, 
inflammatory diseases, angiogenesis, apoptosis inhibition, 
and regulation of extracellular matrix in tumor metastasis. In 
atherosclerotic plaques, high levels of OPN mRNA and proteins 
have been reported (8). In a study by Isoda et al. (9) it was found 
that OPN transgenic mice fed an atherogenic diet developed larger 
atherosclerotic lesions compared to non OPN transgenic mice. 
All of these findings suggest a role of OPN in atherosclerosis. In 
some human studies, blood OPN level was detected to be higher 
in patients with coronary artery disease than in controls (10).
Endothelial dysfunction, which is a prominent cardiovascular risk 
factor, is also an important marker. Noninvasive flow-mediated 
artery dilatation (FMD) technique measures an endothelial 
function-FMD-from brachial artery and it has been used as an 
assessment method of cardiovascular risk in several clinical 
studies (11). In a healthy human, normal FMD is 7-10% of baseline 
artery diameter. However, in patients with cardiovascular disease, 
FMD value is 0-5% of baseline value or it cannot be measured. 
Many studies suggest that endothelial dysfunction detected by 
FMD may be an independent marker to predict cardiovascular 
events (12).
The aim of our study was to assess FMD value, which is an 
atherosclerotic risk marker in hypothyroidism patients, and to 
investigate whether plasma OPN level is a parameter which can 
predict cardiovascular risk in this group of patients. 
Materials and Methods
This study included premenopausal women between the ages 
of 20 and 45 years who were admitted to the Başkent University 
Faculty of Medicine, Department of Endocrinology and Metabolism 
Diseases and who were detected to have thyroid-stimulating 
hormone (TSH) elevation for the first time. Patients who had a 
history of atherosclerotic disease, diabetes mellitus, hypertension, 
hyperlipidemia, or smoking were excluded. Premenopausal 
women, whose thyroid function tests and thyroid autoantibodies 
were normal, were included in this study as euthyroid control 
group. The study complied with the declaration of Helsinki and 
was approved by the local research ethics committee. All the 
subjects gave written informed consent.
At first presentation, weight and height of all subjects were 
measured. Body mass index (BMI) was measured by dividing 
weight (in kilograms) by height (in meters) squared (BMI=weight/
height2). In the beginning, after at least 8 hours of overnight fasting, 
plasma TSH, free thyroxine (fT4), antithyroglobulin antibody (ATA), 
anti-thyroidperoxidase antibody (anti-TPO), fibrinogen, hsCRP, 
fasting plasma glucose, total cholesterol (T-chol), LDL, high density 
lipoprotein cholesterol (HD), and triglyceride levels were measured. 
In addition, endothelium-dependent FMD was measured in all 
patients by high resolution ultrasonography. For OP measurement, 
plasma samples were preserved at -80 °C. 
Then, 1.6-1.8 mcg/kg levothyroxine was introduced to the patients 
with high TSH levels. At the end of the 3-month follow-up period, 
when euthyroidism (TSH normalization: 0.4-4.6 µIU/mL) was 
achieved, all of the initial parameters were reassessed. 
Serum TSH levels were measured using the chemiluminescence 
method with Abbott-Architect analyzer (Chicago, IL, USA) 
and ATA and anti-TPO levels were measured using the 
electrochemiluminescence method with Modular E170 analyzer 
(Roche Diagnostic, Mannheim, Germany). 
Plasma fibrinogen levels were measured using the Clauss clotting 
method with BCT autoanalyzer (Siemens Healthcare Diagnostics, 
Newark, USA), serum alanine aminotransferase (ALT), T-chol, 
HDL and triglyceride levels were measured using the original 
kits of Roche Modular autoanalyzer (Roche Diagnostic GmbH, 
Mannheim, Germany). LDL levels were measured using Friedewal 
formula. 
hsCRP levels were measured using the particle-enhanced 
immunonephelometric method with BN II System (Siemens 
Healthcare Diagnostics, Marburg, Germany).
Complete blood count (CBC) measurement was performed using 
automated cell counter (Cell-Dyn 3700, Abbott Diagnostics, Abbott 
Park, IL USA).
Endothelium-Dependent Flow-Mediated Dilatation 
Measurement 
FMD measurements were performed by a trained cardiologist 
who was blinded to the thyroid function. An Antares US System 
ultrasound device (Siemens Inc, Mountain, View, CA) and a linear 
probe which had a multifrequency (4-9 MHz) feature were used for 
assessment. The subjects laid in the supine position. Right brachial 
artery was visualized 2-5 cm above the antecubital groove while 
its long axis was parallel to the probe and the first measurement 
of brachial artery diameter was made at rest. The measurement 
was standardized and the distance between the intima of the 
vessel wall close to the probe and media-adventitia of the vessel 
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wall away from the probe was measured. In all measurements, 
B-mode grey scale was used. Just after this measurement, collar 
of the blood pressure monitor was inflated (50 mmHg above 
the systolic pressure) for 5 minutes. Diameter measurement 
(approximately at the same location) was performed again 1 
minute after deflation of the collar. 
After this procedure, a formula (FMD-difference in artery diameter/
baseline artery diameter) was used to calculate FMD (13). 
Osteopontin Measurement 
For OPN assessment, blood samples were collected after an 
overnight fasting and centrifuged plasma was preserved at -80 °C.
OPN levels were measured using a commercial ELISA kit which 
could measure both recombinant and native human OPN (Human 
OPN assay kit, IBL, Gunma, Japan). 
For OPN, sensitivity was 3.3 ng/mL, and intra- and inter-assay 
variability percentages were <5% and <10%, respectively. 
In accordance with the study protocol, the samples were diluted 
in a ratio of 1/5, injected into pits including OPN antibodies and 
incubated for 1 hour at 37 °C. After washing, 100 uL signed OPN 
solution was applied to each pit and kept for 30 m at 4 °C.
After washing, tetramethylbenzidine was used as caloric agent 
and the measurements were performed with automated 
ELISA reader (Tecan Sunrise, Salzburg, Austria) which has an 
absorbance value of 450 nm.
Statistical Analysis 
Statistical analysis of the data were made using SPSS 18.0 package 
program. Categorical variables were summarized as numbers 
and percentages. Numerical measurements were summarized 
as mean and standard deviation (SD) (median and minimum-
maximum values were provided when necessary). Normal 
distribution hypothesis of numerical measurements were tested 
using the Kolmogrov-Smirnov test. Numerical measurements 
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Table 1. Initial demographic features and laboratory parameters of the patient and the control groups 
The patient group (n=39) The control group (n=11) p
Age (years) 35.6±9.9 29.8±8.6 0.09
BMI (kg/m2) 27.3±4.6 22.8±5.6 0.01
Anti-TPO (0-34 IU/mL) 313 (5-1525)  5.3 (2.8-29) <0.001
ATA (0-115 IU/mL) 165.5 (10-1246)  10.3(10-120.7) <0.001
TSH (0.4-4.6 µIU/mL) 19 (6-100)  1.3 (0.4-3.7) <0.001
fT4 (9-25 mol/L) 9.0±3.2  13.7±2.1 <0.001
T-chol (125-200 mg/dL) 207.2±53.1  153.7±33.8 0.01
LDL-chol (60-130 mg/dL) 123.8±44.4 88.8±28.3 0.02
HDL-chol (35-80 mg/dL) 51.4±14.8  49.9±10.1 0.75
Triglyceride (55-175 mg/dL) 227 (41-761)  68 (34-123) 0.01
hsCRP (0.0-6.0 mg/L) 3 (2.8-41.8)  3 (0.4-14) 0.08
Fibrinogen (1.8-3.5 g/L) 3.1  2.5 0.23
OPN (ng/mL) 229.7 (129.7-459.1) 194.6 (34.5-457.8) 0.19
FMD (%) 5.0±1.9 6.8±2.5 0.02
BMI: Body mass index, Anti-TPO: Anti-thyroid peroxidase, ATA: Anti-thyroglobulin, fT4: Thyroxine, TSH: Thyroid stimulating hormone, T-chol: Total cholesterol, LDL-chol: Low 
density lipoprotein cholesterol, HDL-chol: High density lipoprotein cholesterol, hsCRP: High-sensitive C-reactive protein, OPN: Osteopontin, FMD: Flow mediated dilatation 
Table 2. Comparison of pretreatment and 3. month (after euthyroidism was achieved) values of the patient group 
Pretreatment (n=39) (1) Posttreatment (after euthyroidism was achieved) (2) p
TSH (µIU/L) 19 (6-100) 2 (0.3-4.4) p<0.001
T-chol (mg/dL) 207.2±53.1 185.2±41.1 p<0.001
LDL-chol (mg/dL) 123.8±44.4 113.5±35.5 p<0.001
HDL-chol (mg/dL) 51.4±14.8 47.7±10.9 p<0.001
Triglyceride (mg/dL) 227 104 0.11
Fibrinogen (g/L) 3.1±0.8 2.9±0.5 0.63
hsCRP (mg/L) 3 (2.8-41.8) 3 (3-51.4) 0.55
OPN (ng/mL) 229.7 (129.7-459.1) 149.6 (65.9-544) p<0.001
FMD (%) 5.0±1.9 7.1±2.7 p<0.001
TSH: Thyroid stimulating hormone, T-chol: Total cholesterol, LDL-chol: Low density lipoprotein cholesterol, HDL-chol: High density lipoprotein cholesterol, hsCRP: High-sensitive 
C-reactive protein, OPN: Osteopontin, FMD: Flow mediated dilatation
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were compared between the groups using a t-test if conditions 
were met and using the Mann-Whitney U test if conditions were 
not met. Dependent samples t-test was used for pre-and post-
comparison of numerical measurements if conditions were met 
and the Wilcoxon signed-rank test was used if conditions were 
not met. Correlation between OPN and FMD was analyzed using 
the pearson correlation coefficient. Statistical significance was 
accepted as <0.05 in all statistical tests. 
Results
This study included 39 patients with high TSH levels and 11 healthy 
euthyroid control subjects. The patient group consisted of 4 (10.2%) 
subclinical and 35 (89.8%) hypothyroid patients. After 3 months of 
follow-up and treatment, control OPN levels were measured in 28 
and control FMD values were measured in 30 patients. The mean 
(±SD) age was similar between the patient and the control groups 
(35.64±9.98 and 29.81±8.68, respectively) (p=0.09). The mean 
(±SD) BMI value was higher in the patient group than in the control 
group (27.3±4.69 vs. 22.8±5.64 kg/m2, respectively) (p=0.01). Initial 
data of the patient and the control groups are shown in Table 1.
At the beginning of this study, BMI, T-chol, LDL and triglyceride 
levels were statistically significantly higher in the patient group 
than in the control group and the p values were 0.01, 0.01, 0.02, 
and 0.01, respectively. In addition, FMD values were lower in the 
patient group, (p=0.02). Fibrinogen, hsCRP and OPN values were 
similar in the two groups (p>0.05). The mean diastolic blood 
pressure was also higher in the patient group (74.1±9.8 mmHg 
vs. 64.5±9.3 mmHg) (p<0.01).
We compared pretreatment (1) and posttreatment (2) (after 
euthyroidism was achieved) values of several parameters and 
found that T-chol, LDL, HDL and OPN values significantly decreased 
and FMD significantly increased. No significant difference was 
observed in other follow-up parameters (Table 2). Changes in 
OPN and FMD are schematized in Figure 1 and Figure 2. 
Comparison between values of the patient group after 
euthyroidism was achieved (post treatment) and the initial 
values of the control group are given in Table 3. T-chol, LDLc and 
triglyceride levels were higher in the patient group than in the 
control group even after euthyroidism was achieved. 
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Table 3. Comparison of follow up parameters of the patient group after euthyroidism was achieved (post treatment) with baseline values of the 
control group 
Patient group (post treatment) (n=39) Control group (n=11) p
TSH (µIU/L) 2 (0.3-4.4) 1.3 (0.4-3.7) 0.27
T-chol (mg/dL) 185.2±41.1 153.72±33.8 0.02
LDL-chol (mg/dL) 113.5±35.5 88.8±28.3 0.04
HDL-chol (mg/dL) 47.7±10.9 49.9±10.1 0.55
Triglyceride (mg/dL) 104 (45-481) 68 (34-123) 0.01
Fibrinogen (g/L) 2.8 (2-4.7) 2.5 (2-30) 0.37
OPN (ng/mL) 149.6 (65.9-544) 194 (34.5-487.8) 0.43
FMD (%) 7.5 (3-15.2) 6.5 (2-10.2) 0.75
TSH: Thyroid stimulating hormone, T-chol: Total cholesterol, LDL-chol: Low density lipoprotein cholesterol, HDL-chol: High density lipoprotein cholesterol, OPN: Osteopontin, 
FMD: Flow mediated dilatation
Figure 1. Pretreatment (1) and post treatment (after euthyroidism was 
achieved) (2) levels of osteopontin in the patient group (p<0.001)
Figure 2. Percentage change in flow mediated arterial dilatation between 
pretreatment and post treatment (after euthyroidism was achieved) 
measurements of the patient group (p<0.001)
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In the patient group, we could not detect a correlation between 
OPN and FMD in pretreatment and posttreatment measurements 
(pretreatment OPN-FMD; r=-0.17, p=0.29, posttreatment OPN-
FMD; r=-0.00, p=0.99). 
We tested the correlation between baseline OPN level and 
pretreatment levels of all the parameters in the patient group and 
found only a weak negative correlation between diastolic blood 
pressure and OPN level (r=-0.392, p=0.027). Also, there was no 
correlation between post-treatment OPN level and baseline or 
posttreatment levels of all parameters.
After euthyroidism was achieved in the patient group, correlation 
between percentage change in OPN levels and follow-up 
parameters were analyzed. Positive correlations were observed 
between OPN change (%) and baseline T-chol (r=0.55, p=0.005), 
LDL (r=0.56, p=0.004), fibrinogen (r=0.52, p=0.006), and 
posttreatment T-chol (r=0.48, p=0.01), and LDL (r=0.44, p=0.02) 
levels. 
Discussion
Epidemiological studies have shown accelerated coronary 
atherosclerosis in hypothyroidism. Atherosclerotic risk factors 
associated with hypothyroidism are hypercholesterolemia, 
hypertension, endothelial dysfunction, hyperhomocysteinemia 
and increased C-reactive protein level (14). 
Previous studies have shown that cholesterol level may be more 
than 50% or higher in patients with hypothyroidism than that 
in controls (15). T-chol and LDL levels were correlated with high 
TSH levels detected in hypothyroidism and this suggested that 
lipid dysfunction was due to thyroid hormone deficiency (16). In 
our study, initial T-chol, LDL and triglyceride levels were elevated 
in accordance with the literature. We also detected significant 
decreases in T-chol and LDL and nonsignificant decrease in 
triglyceride levels after achievement of euthyroidism with thyroxine 
treatment. 
A study by Verdugo et al. (17) showed a trend to decrease in 
HDL levels with thyroid hormone replacement treatment. In 
another study, hypothyroidism was associated with low HDL 
level and, after TSH normalization with thyroxine treatment, this 
level increased (18,19,20). In our study HDL level decreased with 
thyroxine treatment. 
Fibrinolytic activity decreases in subclinical hypothyroidism. In 
these patients, there is a tendency for thrombosis; in contrast, in 
hypothyroidism, there is a tendency for bleeding (21). In our study, 
fibrinogen levels were measured to evaluate clotting system and, 
no difference was found between hypothyroidism patients and 
controls. Similarly, fibrinogen levels did not decrease in the patient 
group after achievement of euthyroidism with thyroxine. 
In another study, TSH level was found to be significantly 
associated with BMI and waist circumference and, BMI increased 
with increasing TSH levels. Higher BMI values in hypothyroidism 
patients than in controls in our study may be explained by this 
fact (22). Although in a study including obese, overweight and 
normal weight individuals, circulating OPN level was significantly 
higher in obese and overweight individuals than in normal weight 
subjects (23), we could not find a positive correlation between 
BMI and OPN levels. This may be due to small sample size in 
our study. 
The patient and the control groups in our study involved only 
premenopausal women. According to a study by Cho et al. (24) 
which investigated the association between serum OPN level and 
BMD, postmenopausal women had higher serum OPN levels 
than premenopausal women. We could not evaluate this topic 
because our study did not involve any postmenopausal woman. 
Reza et al. (25) found that OPN was upregulated in several 
patients with hyperthyroidism and downregulated in hypothyroid 
patients. While OP was positively correlated with fT3 and fT4, it was 
negatively correlated with TSH and a significant correlation was 
found between them. The authors suggested that OPN might be 
useful as a novel prognostic biomarker in patients with impaired 
thyroid function. We found similar OPN levels in hypothyroid 
and euthyroid patients. The aforementioned difference could be 
missed in our study due to small sample size. 
In a study on osteoprotegerin (OPG), which is in same class with 
OPN, it was found that OPG significantly elevated in hypothyroidism 
and significantly decreased with thyroid replacement. In that study 
OPG levels were correlated with vascular damage independent 
from the severity of hypothyroidism (26). In the same study, a 
positive correlation was detected between TSH and OPG levels 
but an association was not detected between OPG level and 
T-chol, LDL and HDL levels. No relationship was detected between 
baseline levels of serum lipids or changes in the lipid levels and 
OPG levels after thyroxine treatment. Also no relationship was 
detected between hemodynamic parameters such as systolic and 
diastolic blood pressures and OPG levels (26).
In a study involving 409 patients (280 patients with coronary 
artery disease and 129 patients without coronary artery disease) 
carotid-femoral pulse wave velocity (PWV) was used as aortic 
stiffening index and OPN and osteoprotogerinin were used as 
vascular remodeling and calcification markers. Plasma OPN 
and OPG were found to be associated with arterial stiffness. The 
first findings of this study suggested that OPN and OPG were 
associated with the pathogenesis of atherogenesis in coronary 
artery disease. In patients with coronary artery disease, higher 
levels of OPG and OPN and impaired carotid-femoral PWV were 
detected compared with patients without coronary artery disease. 
In addition, PWV was found to be associated with OPG and OPN 
levels. Linear regression analyses showed that plasma OPG and 
OPN levels increased independent from other cardiovascular 
risk factors (27). We could not find a significant difference in OPN 
levels between patients with hypothyroidism and controls, but 
after treatment of hypothyroidism, plasma OPN levels significantly 
decreased. FMD values in hypothyroidism patients were lower 
than in controls. After thyroxine treatment, FMD values significantly 
increased. However, in contrast to a study by Tousoulis et al. (27) 
who detected an association between PWV and OPN, we could 
not detect an association between OPN and FMD.
FMD reflects early phases of atherosclerosis. In hypothyroidism, 
flow-related, endothelium-dependent vasodilatation has 
been shown to be impaired like in patients who were at early 
phases of atherosclerosis. It is not clear whether this alteration 
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is a direct effect of thyroid hormone deficiency or effect of 
hypercholesterolemia secondary to hypothyroidism (28). A 
prospective study by Akcakoyun et al. (29) evaluated endothelial 
functions in 135 patients who underwent coronary artery 
stenting under elective conditions with FMD. Measurements 
were made before and after stenting procedure. FMD was 
significantly lower in patients who suffered from a vascular 
event than patients who did not suffer from a vascular event 
(4.7±1.9% and 6.0±2.0%, respectively, p=0.007) (29). Similar 
studies by Fathi et al. (30) and Neunteufl et al. (31), showed 
that low FMD was associated with higher frequency of 
cardiovascular events. In our study, hypothyroidism patients 
had lower FMD than controls at the time of diagnosis, as 
expected. After achievement of euthyroidism with thyroxine 
treatment, FMD increased significantly approaching euthyroid 
control group. 
As a result, animal studies and experimental studies dominate 
literature about OPN. OPN use in human studies is for now 
inadequate. We could not detect a significant correlation between 
OPN and cardiovascular risk parameters and, therefore, we 
cannot recommend the use of OPN as a cardiovascular risk 
marker. Larger scale studies are needed to show the presence 
of such an association. 
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